key: cord-1018345-juzooq1h authors: Galland, Joris; Thoreau, Benjamin; Delrue, Maxime; Neuwirth, Marie; Stepanian, Alain; Chauvin, Anthony; Dellal, Azeddine; Nallet, Olivier; Roriz, Melanie; Devaux, Mathilde; London, Jonathan; Martin‐Lecamp, Gonzague; Froissart, Antoine; Arab, Nouara; Ferron, Bertrand; Groff, Marie‐Helene; Queyrel, Viviane; Lorut, Christine; Regard, Lucile; Berthoux, Emilie; Bayer, Guillaume; Comarmond, Chloe; Lioger, Bertrand; Mekinian, Arsène; Szwebel, Tali‐Anne; Sené, Thomas; Amador‐Boreiro, Blanca; Mangin, Olivier; Sellier, Pierre‐Olivier; Mouly, Stephane; Kevorkian, Jean‐Philippe; Siguret, Virginie; Vodovar, Dominique; Sene, Damien; Mathieu, Albertini; Sara, Bouajila; Kimbimbi, Britany; Ruxandra, Burlacu; Léa, Cacoub; Karine, Champion; Véronique, Delcey; Jean‐Guillaume, Dillinger; Florine, Feron; Aline, Frazier; Funck‐Bretano, Thomas; Diane‐Cecile, Gauthier; Jean‐François, Gautier; Patrick, Henry; Tessa, Huscenot; Izabel, Sarah; Jaulerry, Mathilde; Moenes, Jouabli; Jean‐Baptiste, Julla; Marie, Laloi Michelin; Pierre, Leroy; Amanda, Lopes; Bruno, Megarbane; Maxime, Michon; Anne‐Lise, Munier; Yoram, Nahmani; Martin, Nicol; Eroan, Nicolas; Audrey, Poulat; Eric, Revue; Pascal, Richette; Jean‐Pierre, Riveline; Emma, Rubenstein; Adrien, Zanin; Clément, Aveneau; Paul, Bastard; Diane, Beauvais; Loredana, Boghez; Alix, Borderiou; Paul, Conway; Lavignia, Cosma; Vincent, Davy; Clément, Desjardin; Sandra, Devatine; Christel, Ducroz Gerardin; Charlotte, Dupe; Chloé, Gobert; Clotilde, Gros; Soumaya, Kadiri; Enmat, Khan; Sandrine, Ongnessek; Fatima, Rhmari; Isabelle, Sacco; Natalia, Saptefrat; Pauline, Schaupp; Justine, Serre; Georgios, Sideris; Sonia, Smati; Marine, Tournier; Pauline, Treca; Tony, Truong; Mathilde, Tuffier; Mattéo, Arcelli; Yvonnick, Boue; Alban, Copie; Nicolas, Deye; Jean‐Michel, Ekherian; Zaccaria, Errabih; Antoine, Gonde; Caroline, Grant; Emmanuelle, Guerin; Adèle, Magalhaes; Isabelle, Malissin; Edouard, Meurisse; Aymen, Mrad; Giulia, Naim; Philippe, Nguyen; Kiyoko, Nitenberg; Adrien, Pepin‐Lehalleur; Arthur, Perault; Lucile, Perrin; Maxime, Renaud; Laetitia, Sutterlin; Maxime, Delrue; Virginie, Siguret; Alain, Stepanian title: White blood count, D‐dimers, and ferritin levels as predictive factors of pulmonary embolism suspected upon admission in noncritically ill COVID‐19 patients: The French multicenter CLOTVID retrospective study date: 2021-05-24 journal: Eur J Haematol DOI: 10.1111/ejh.13638 sha: 2284eb49999a07430b11aa1b49c01e91a30affaa doc_id: 1018345 cord_uid: juzooq1h BACKGROUND: A high prevalence of pulmonary embolism (PE) has been described during COVID‐19. Our aim was to identify predictive factors of PE in non‐ICU hospitalized COVID‐19 patients. METHODS: Data and outcomes were collected upon admission during a French multicenter retrospective study, including patients hospitalized for COVID‐19, with a CT pulmonary angiography (CTPA) performed in the emergency department for suspected PE. Predictive factors significantly associated with PE were identified through a multivariate regression model. RESULTS: A total of 88 patients (median [IQR] age of 68 years [60‐78]) were analyzed. Based on CTPA, 47 (53.4%) patients were diagnosed with PE, and 41 were not. D‐dimer ≥3000 ng/mL (OR 8.2 [95% CI] 1.3‐74.2, sensitivity (Se) 0.84, specificity (Sp) 0.78, P = .03), white blood count (WBC) ≥12.0 G/L (29.5 [2.3‐1221.2], Se 0.47, Sp 0.92, P = .02), and ferritin ≥480 µg/L (17.0 [1.7‐553.3], Se 0.96, Sp 0.44, P = .03) were independently associated with the PE diagnosis. The presence of the double criterion D‐dimer ≥3000 ng/mL and WBC ≥12.0 G/L was greatly associated with PE (OR 21.4 [4.0‐397.9], P = .004). CONCLUSION: The white blood count, the D‐dimer and ferritin levels could be used as an indication for CTPA to confirm PE on admission in non‐ICU COVID‐19 patients. The high prevalence of thrombotic events would be related to the combination of hypoxia with an immune-triggered thromboinflammation responsible for endothelial injuries and coagulability disorders. [9] [10] [11] [12] Many patients during COVID-19 infection often present with an increased plasma D-dimer concentration that reflects, in that context, both the coagulation disorder and inflammatory state. Such an increase has been previously identified as one of the predictors of intensive care unit (ICU) admission and death. 1, 4, 11, 13, 14, 15 Moreover, some authors have proposed plasma D-dimer thresholds for predicting the diagnosis of pulmonary embolism (PE) during COVID-19 infection. 15, 16 However, most of these studies did not differentiate ICU and non-ICU patients. While the prevalence of PE in ICU COVID-19 patients ranges from 13.6% to 23.1%, the exact prevalence of PE in COVID-19 patients hospitalized in non-critical medicine departments (non-ICU patients) remains between 1.6% and 8%. [17] [18] [19] [20] [21] [22] Improved prediction of PE in this population would allow a better targeting of patients at high risk of PE and could help guide the prescription of anticoagulant therapy. It would decrease PE-related transfer in the ICU and mortality. 23 The objective of our study was to identify clinical, laboratory, and CT-scan predictive factors of PE in hospitalized non-ICU COVID-19 patients upon admission. The CLOTVID study is a multicenter retrospective study conducted from April 6 to April 28, 2020, in 18 participating French hospitals located in 12 cities (five university hospitals and seven non-university hospitals). All adults (≥18 years old) with laboratory-confirmed COVID-19 infection (positive RT-PCR) and in whom a CT pulmonary angiography (CTPA) were performed for clinical suspicion of PE on admission to the emergency department (ED), and before being hospitalized in one of the participating medicine ward, were included. We excluded patients with clinical suspicion of PE and/or patients diagnosed with deep vein thrombosis (DVT) for whom CTPA was not performed on ED admission. We also excluded patients directly admitted to the ICU and then transferred to the medicine ward. For each patient, the data collected included demographics (age, gender and body mass index (BMI)), medical background (comorbidities and previous long-term curative/prophylactic anticoagulation therapy), COVID-19 infection history (date of the first symptoms, date of hospital admission, and date of positive RT-PCR), symptoms, and vital parameters on admission. A radiologist blinded to the hypothesis locally reviewed each CTPA, analyzing the type of lesion (ground glass and/or condensation) and their extension (absent (<10%), minimal (10%-25%), moderate (25%-50%), extensive (50%-75%), and severe (>75%)). 24 We also collected laboratory tests on admission (white blood count (WBC), serum creatinine level, C-reactive protein (CRP), serum ferritin, prothrombin time ratio, fibrinogen, plasma D-dimers, brain natriuretic peptide (BNP), and troponin), both nonspecific (oxygen and ventilator support) and possibly specific treatment of the COVID-19 infection (antiviral therapy, hydroxychloroquine, steroids, and biotherapies) and outcome during the follow-up (death/ICU admission or recovery). Continuous variables are expressed as median (interquartile range) and categorical variables as number (percentage). Univariate analysis was performed using Mann-Whitney-U, t-Student, chi 2 and Fisher's exact tests, as appropriate. Significant variables with P-value ≤.2 in the univariate regression were selected as candidates for the multivariate logistic regression model. Biomarkers were considered both directly and after conversion into a binary variable using a threshold determined by a receiver operating characteristic (ROC) curve analysis. We chose the threshold with the best specificity-sensitivity ratio to discriminate between patients with and without a PE diagnosis. Results are expressed as odds ratios (OR) with their 95% confidence intervals (CI). We also tested by a logistic regression the association between PE and the presence of double criterion associating D-dimers ≥3000 ng/mL and WBC ≥12 G/L, based on their respective thresholds. The discriminative capacity of the predictive factors identified was illustrated via their sensitivity, their specificity, based on a prevalence fixed at 5%, their positive (PPV) and negative predictive value (NPV). In addition, the Wells' score modified for PE alone and the Wells' score associated with D-dimer level adjusted on age were retrospectively calculated for each patient. 25 Finally, the ROC curves and area under curve (AUC) between each biomarkers identified and wells' score were compared with DeLong's test. 26 A P-value of <.05 was considered statistically significant. No imputation method was used for missing unrecoverable data. Data were analyzed using R software, v3. 6 This non-interventional study was based on medical records, which were in strict compliance with the French reference meth- Overall 191 patients were included from the 18 French COVID-19 units and 103 patients were excluded ( Figure 1) Patients diagnosed with PE less frequently had diabetes mellitus and were less frequently obese (BMI > 30 kg/m 2 , P < .05 for both). Three Blinded analysis of CTPA found similar proportions of ground glass and consolidation between the two groups (P > .05), and a similar extension of lung lesions between the two groups (P = .08). PE was segmental in half of the cases (N = 23-48.9%) and proximal in 44.7% of the cases. The remaining cases were sub-segmental (N = 3-6.4%) (Table S1 ). PE was bilateral in 44.7% of patients. Laboratory parameters on admission differed between the two groups. WBC and the ferritin level were higher in the PE group ( Figure 2 ; P < .001 and P = .01, respectively) while C-reactive protein, elevated in 93% of patients, did not significantly differ (P = .9). The prothrombin time ratio was lower and D-dimer levels were 6fold higher in the PE group than in the non-PE group (P = .01 and P < .0001, respectively). Platelets and fibrinogen were not different (P = .8 and .5, respectively). Cardiac and renal biomarkers were similar between the two groups. No association was found between WBC, or the D-dimer level, or the ferritin level or the prothrombin time ratio and the extension of lung lesions on the HRCT (all P > .05, Figure S1 ). There was no difference in the use of antibiotics, antiviral therapies, corticosteroids or biotherapies between the groups (P > .05 for all) during the hospitalization in medicine wards. All patients diagnosed with PE received anticoagulation therapy including therapeutic doses of low-molecular-weight heparin (LMWH; N = 33-70.2%), unfractionated heparin (N = 9-19.1%), or direct-acting oral anticoagulant (N = 4-8.5%) ( Table S1 ). The follow-up period (19 days [14-25]) was similar in the PE and non-PE groups. At the end of the inclusion, 17 (19.3%) patients died or were transferred to the ICU, 52 (59.1%) were discharge from the hospital, and 19 (21.6%) remain hospitalized with no difference between the two groups. We interpreted biomarkers as binary variables based on the best specificity-sensitivity ratio using ROC curves ( Figure 3 ). Univariate analysis showed that D-dimer level ≥3000 ng/mL, WBC ≥12.0 G/L, prothrombin time ratio >1.05 (P < .001 for all), and ferritin level ≥480 µg/L (P < .01) were associated with an increased risk of PE, whereas the presence obesity and diabetes mellitus were not associated with an increased risk of PE (Table 2 ). Multivariate analysis showed that only D-dimer ≥3000 ng/mL (OR 8. 19 [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] 19 [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] 17 [13] [14] [15] [16] [17] [18] [19] . Figure S2 ). Herein, we report easily available three laboratory markers routinely measured upon patient admission, with a greater impact than clinical and radiological data in the early triage of COVID-19 patients. These laboratory results were strongly and independently associated with PE. All these findings support the hypothesis that the sensitivity of the conventional strategies for PE suspicion might be insufficient. The plasma D-dimer threshold for excluding thromboembolism is not comparable to that of a non-COVID-19 population (Ddimers: 3000 ng/mL in a COVID-19 population vs 500 ng/mL in a non-COVID-19 population). 31 This thrombogenic process is involved in venous and arterial macrovascular thrombotic events. 34 infection is estimated to be between 5% and 30%, depending on the series. 6, 16, 17, 20, 21, 22, 42 However, many studies have not distinguished between patients hospitalized in the ICU or not and, consequently, have overestimated the real prevalence in the medical ward. Some studies have specifically described the prevalence of PE in non-ICU patients between 1.6% and 8%. [20] [21] [22] Our study has limitations: limited numbers of patients, descriptive study, and enrollment of patients with PE excluding other arterial or DVT. Nevertheless, these predictive factors may help quickly to determine the risk of PE upon admission, thus allowing for the rapid prescription of CTPA and anticoagulant treatment in EDs, and they seem to be more accurate than the currently used scores (eg, The white blood count, and the D-dimer and ferritin levels are Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention Clinical characteristics of coronavirus disease 2019 in China COVID-19 and its implications for thrombosis and anticoagulation COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy ISTH interim guidance on recognition and management of coagulopathy in COVID-19 Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Respiratory mechanics and gas exchanges in the early course of COVID-19 ARDS: a hypothesisgenerating study Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Pulmonary Embolism in Patients With COVID-19 High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients Thrombosis in hospitalized patients with COVID-19 in a New York City health system Incidence of venous thromboembolism in hospitalized patients with COVID-19 Acute pulmonary embolism and COVID-19 Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 COVID-19 patients and the radiology department -advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI) Further validation and simplification of the Wells clinical decision rule in pulmonary embolism Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected with Pulmonary CT Angiography D-Dimer Level and Neutrophils Count as Predictive and Prognostic Factors of Pulmonary Embolism in Severe Non-ICU COVID-19 Patients Characteristics of acute pulmonary embolism in patients with COVID-19 associated pneumonia from the city of Wuhan Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer Prediction of pulmonary embolism in the emergency department: the revised Geneva score High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction Neutrophil extracellular trap (NET) impact on deep vein thrombosis Clinical and immunological features of severe and moderate coronavirus disease 2019 Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China COVID-19: in the eye of the cytokine storm Thrombosis at hospital presentation in patients with and without coronavirus disease 2019 Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19 Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19 High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients Additional supporting information may be found online in the Supporting Information section.